The landscape of multiple myeloma treatment has undergone a profound transformation with the advent of monoclonal antibodies (mAbs) targeting CD38. Among the notable breakthroughs, two anti-CD38 mAbs, DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), have been approved for clinical use. These groundbreaking mu...
Find MoreStep aside, CAR-Ts; with three FDA approvals, the class of bispecific antibodies has begun to take on the relapsed/refractory multiple myeloma treatment segment. Currently, the US Food and Drug Administration (FDA) has authorized 10 bispecific antibodies and one bispecific molecule, the majority of which are a...
Find MoreMultiple myeloma is the second most prevalent blood cancer diagnosis in the United States, after non-Hodgkin lymphoma. Males are significantly more likely than females to have multiple myeloma. Myeloma incidence is highly tied to age, with older adults having the highest incidence rates and being diagnosed most fre...
Find MoreOver the years, REVLIMID has become an integral weapon in the cancer therapeutics’ armory. This odyssey of REVLIMID in the multiple myeloma segment began in 2005, when it was approved by the US FDA for the treatment of adult patients with multiple myeloma, in combination with dexamethasone. As the wise say...
Find MoreAmgen Reports Promising Mid-stage Results for its Olpasiran Candidate Amgen has reported encouraging mid-stage results for its olpasiran candidate for lowering lipoprotein(a) - a risk factor for atherosclerotic cardiovascular disease - and now plans to move forward with a phase III program as soon as possi...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.